- TABLE OF CONTENTS
- Hepatocellular Cancer
- Biliary Tract Cancers
- Suggested Reading
Suggested Reading
On Hepatocellular Carcinoma
Abou-Alfa GK, Johnson P, Knox JJ, et al: Doxorubicin(Drug information on doxorubicin) plus sorafenib(Drug information on sorafenib) vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA 304:2154–2160, 2010.
Andolino DL, Johnson CS, Maluccio M, et al: Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81:e447–e453, 2011.
Bhoori S, Schiavo M, Russo A, Mazzaferro V: First-line treatment for hepatocellular carcinoma: Resection or transplantation? Transplant Proc 39:2271–2273, 2007.
Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34, 2009.
Cheng BQ, Jia CQ, Liu CT, et al: Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: A randomized controlled trial. JAMA 299:1669–1677, 2008.
Finn RS, Kang YK, Mulcahy M, et al: Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18:2090–2098, 2012.
Gupta S, Bent S, Kohlwes J: Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C: A systematic review and critical analysis. Ann Intern Med 139:46–50, 2003.
Imamura J, Tateishi R, Shiina S, et al: Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol 103:3057–3062, 2008.
Llovet J, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37:429–442, 2003.
Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390, 2008.
Marrero JA, Lencioni R, Kudo M, et al: Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. J Clin Oncol 29(s):abstract 4001.
Mok TS, Yeo W, Yu S, et al: An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. J Clin Oncol 23:8041–8047, 2005.
Morimoto M, Numata K, Kondou M, et al: Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: A randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 116:5452–5460, 2010.
Salem R, Lewandowski RJ, Kulik L, et al: Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497–507, 2011.
Sangro B, Carpanese L, Cianni R, et al: Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: A European evaluation. Hepatology 54:868–878, 2011.
Thomas MB, Jaffe D, Choti MM, et al: Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28:3994–4005, 2010.
Varela M, Real MI, Burrel M, et al: Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481, 2007.
Yao FY, Bass NM, Ascher NL, Roberts JP: Liver transplantation for hepatocellular carcinoma: Lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Liver Transpl 10:621–630, 2004.
Zhang BH, Yang BH, Tang ZY: Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417–422, 2004.
On Gallbladder Tumors
Cho SY, Kim SH, Park SJ, et al: Adjuvant chemoradiation in gallbladder cancer. J Surg Oncol 102:87–93, 2010.
Patt YZ, Hassan MM, Aguayo A, et al: Oral capecitabine(Drug information on capecitabine) for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101:578–586, 2004.
Takada T, Amano H, Yasuda H, et al: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685–1695, 2002.
Wang SJ, Lemieux A, Kalpathy-Cramer J, et al: Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 29:4627–4632, 2011.
On Bile Duct Tumors
Alberts SR, Al-Khatib H, Mahoney MR, et al: Gemcitabine(Drug information on gemcitabine), 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: A North Central Cancer Treatment Group phase II trial. Cancer 103:111–118, 2005.
Bekaii-Saab T, Phelps MA, Li X, et al: Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29:2357–2363, 2011.
Cheng Q, Luo X, Zhang B, et al: Predictive factors for prognosis of hilar cholangiocarcinoma: Postresection radiotherapy improves survival. Eur J Surg Oncol 33:202–207, 2007.
Gruenberger B, Schueller J, Heubrandtner U, et al: Cetuximab(Drug information on cetuximab), gemcitabine, and oxaliplatin(Drug information on oxaliplatin) in patients with unresectable advanced or metastatic biliary tract cancer: A phase 2 study. Lancet Oncol 11:1142–1148, 2010.
Horgan AM, Amir E, Walter T, Knox JJ: Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis. J Clin Oncol 30:1934–1940, 2012.
Knox JJ, Hedley D, Oza A, et al: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial. J Clin Oncol 23:2332–2338, 2005.
Lubner SJ, Mahoney MR, Kolesar JL, et al: Report of a multicenter phase II trial testing a combination of biweekly bevacizumab(Drug information on bevacizumab) and daily erlotinib in patients with unresectable biliary cancer: A phase II Consortium study. J Clin Oncol 28:3491–3497, 2010.
Rea DJ, Heimbach JK, Rosen CB, et al: Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242:451–461, 2005.
Valle J, Wasan H, Palmer DH, et al: Cisplatin(Drug information on cisplatin) plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281, 2010.
